BACKGROUND: Circadian variation in @entity8 of @entity581 has been demonstrated in animal and @entity1 studies. @entity1 with @entity1577 are frequently prescribed @entity581 . Altered pharmacokinetics of @entity581 are predictive of @entity137 . AIM: To investigate whether the time of day of @entity5292 administration modulates renal excretion of @entity2890 and @entity137 in @entity1 with @entity1577 . To determine whether circadian rhythms are disrupted in @entity1 with @entity1577 during hospital admission. METHODS: @entity1 (age 5-18years) with @entity1577 scheduled for @entity2890 therapy were randomly allocated to receive @entity2890 at 0800 or 2000h. Serum @entity2890 levels were drawn at 1h and between 3.5 and 5h post-infusion between days 5 and 9 of therapy. @entity2493 levels were measured serially at intervals from 1800h in the evening until 1200h on the next day. Circadian rhythm was categorised as normal when dim light @entity2493 onset was demonstrated between 1800 and 2200h and/or peak @entity2493 levels were observed during the night. Weight and spirometry were measured at the start and end of the therapy. Urinary biomarkers of @entity8 ( @entity31309 , @entity11690 , @entity15901 , @entity8923 and CysC) were assayed at the start and end of the course of @entity2890 . RESULTS: Eighteen @entity1 were recruited to the study. There were no differences in renal clearance between the morning and evening groups. The increase in urinary @entity31309 was greater in the evening dosage group compared to the morning group (mean difference, 0.73ng/mg; 95% CI, 0.14 to 1.32; p=0.018). There were no differences in the other urinary biomarkers. There was normal circadian rhythm in 7/11 @entity1 (64%). CONCLUSIONS: Renal elimination of @entity2890 was not affected by the time of day of administration. Urinary @entity31309 raises the possibility of greater nephrotoxicity with evening administration. Four @entity1 showed disturbed circadian rhythm and high @entity2493 levels (ClinicalTrials.gov NCT01207245).

The pharmacokinetics and @entity137 of morning vs. evening XXXX dosing for pulmonary exacerbations of @entity1577 : A randomised comparison.

@entity1 :: ('9606', 'Species') :: ['participants', 'children', 'human', 'Children', 'People'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal toxicity', 'kidney toxicity'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2890 :: ('MESH:D014031', 'Chemical') :: ['tobramycin'] @entity5292 :: ('D000617', 'Chemical') :: ['aminoglycoside'] @entity2493 :: ('MESH:D008550', 'Chemical') :: ['Melatonin', 'melatonin'] @entity11690 :: ('51594', 'Gene') :: ['NAG'] @entity8923 :: ('3606', 'Gene') :: ['IL-18'] @entity581 :: ('MESH:D000617', 'Chemical') :: ['aminoglycosides'] @entity15901 :: ('3934', 'Gene') :: ['NGAL'] @entity1577 :: ('MESH:D003550', 'Disease') :: ['CF'] @entity31309 :: ('26762', 'Gene') :: ['KIM-1', 'KIM1']
@entity2890 :: (MESH:D014031,Chemical) :: ['tobramycin']
